3928 Varsity Drive
56 articles with Zomedica Pharma
Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.) (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic products for companion animals, announced that it has changed its legal name to Zomedica Corp. The Company’s stock trading symbol will remain as ZOM on the NYSE American and the shares will begin trading under the new name effective on October 5, 2020. The Company’s board
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for companion animals, today announced the voting results of its 2020 Annual and Special Virtual-Only Meeting of Shareholders (the “ Meeting”). At the Meeting, the Company’s shareholders approved the following proposals: Election of Jeffrey Rowe, Robert Cohen, Johnny D. Powers, Rodney
- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), a veterinary health company creating point-of-care diagnostics products for companion animals, announced today that Robert Cohen, Interim Chief Executive Officer, and Stephanie Morley, President and Chief Medical Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference. The presentation is scheduled for September 14, 2020 at 4:00 pm ET. The slides to be p
Zomedica to Develop Gastrointestinal Testing Panel for TRUFORMA™Three new assays to be added to the five assays currently under development
to target diagnosis of canine gastrointestinal issues. The new assays are in addition to the initial five assays currently under development, including panels for adrenal and thyroid testing, for TRUFORMA™, Zomedica's point-of-care veterinary diagnostic platform.
Zomedica Announces Letter From Robert Cohen, Interim CEO, Made Available to Shareholders in Connection With Annual and Special Virtual-Only Meeting
Zomedica Pharmaceuticals Corp. announced that the following letter from Robert Cohen, Interim Chief Executive Officer, has been made available to shareholders.
Zomedica Pharmaceuticals Corp., a veterinary health company, announced that Shameze Rampertab has resigned as Chief Financial Officer and member of the Board of Directors, effective August 14, 2020.
Successful Remote Installation of TRUFORMA™Permits Validation and Pilot Program Progress During COVID-19 Restrictions
Zomedica Pharmaceuticals Corp., a veterinary health company, announced that, in response to the COVID-19 crisis, it successfully implemented its first completely remote installations of TRUFORMA™, the Company's inaugural point-of-care diagnostic device. Remote installation has enabled Zomedica to proceed with validation testing with its clinical College of Veterinary Medicine partners at Auburn, Mississippi State, and Purdue Universities.
Zomedica Pharmaceuticals Corp. announced the pricing of its previously announced public offering of 187,500,000 common shares of the Company, together with short-term warrants to purchase up to 187,500,000 common shares, at a combined public offering price of $0.16 per share and accompanying warrant. Each common share is being sold in the offering together with one two-year warrant to purchase one common share at an exercise price of $0.16 per common share.
Zomedica Completes Verification of Three More Assays for its TRUFORMA™ Point-of-Care Diagnostic PlatformCanine TSH, Feline TSH and Feline total T4 added to Canine total T4
Zomedica, a veterinary diagnostic company, announced that it has completed the final verification of three additional assays for use with its TRUFORMA™ point-of-care diagnostic platform.
Zomedica Completes Verification of its TRUFORMA™ Point-of-Care Diagnostic Platform and the First Assay, Canine total T4Meets Major Development Milestone with Qorvo
Zomedica Pharmaceuticals Corp., a veterinary diagnostic company, announced that it has completed the verification of TRUFORMA™, its point-of-care diagnostic biosensor platform, and the first assay, Canine total T4 thyroxine.
Zomedica Pharmaceuticals Corp. announced that, on April 7, 2020, the Company filed with the United States Securities and Exchange Commission a Current Report on Form 8-K providing an update on the effect of the novel coronavirus pandemic on its operations.
Zomedica Pharmaceuticals Corp., a veterinary diagnostic company, announced the pricing of its previously announced public offering of 33,333,334 common shares and warrants to purchase up to 16,666,667 common shares.
Zomedica Pharmaceuticals Corp. announced that it has commenced a public offering of its common shares and warrants to purchase common shares.
Zomedica Pharmaceuticals Corp., a veterinary diagnostic company, announced consolidated financial results for the year ended December 31, 2019.
ANN ARBOR, Mich., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or “Company”), a veterinary diagnostic company, announced today that it has entered into a definitive agreement with institutional investors for the issuance and sale in a registered direct offering of 20,833,334 of its common shares at a purchase price of $0.12 per share, for gross proceeds of $2.5 million. The offering is expected to close on or about February 14, 2020, sub
Assays expected to be capable of broad-based fecal pathogen identification in minutes for diagnosing infections in dogs and cats - complementary to Zomedica’s development work related to urine pathogens
Large Pennsylvania referral clinic added to University of Georgia
Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America
Zomedica Pharmaceuticals Corp. is pleased to announce that all ordinary and special resolutions were passed at the Annual and Special Meeting of Shareholders, which was held today in Toronto, Ontario, Canada.
Zomedica Commences Final TRUFORMA™ Diagnostic Verification StudyExpects to Commence Commercialization Activities in Q1 2020
Zomedica Pharmaceuticals Corp., a veterinary diagnostic and pharmaceutical company, announced that it has commenced the final verification study of the first five assays designed for use with its point-of-care diagnostic biosensor platform, TRUFORMA™.